Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results. Issue 4 (6th January 2016)

• Record Type: Journal Article
• Authors: Simon-Yarza, M. T.; Baati, T.; Paci, A.; Lesueur, L. L.; Seck, A.; Chiper, M.; Gref, R.; Serre, C.; Couvreur, P.; Horcajada, P.
• Is Part Of: Journal of materials chemistry. Volume 4:Issue 4(2016)
• Page Start: 585
• Page End: 588
• Publication Date: 2016-01-06
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c5tb02084k
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Nanoparticles of a mesoporous iron(iii ) trimesate MIL-100 nanocarrier encapsulating high amounts of the challenging antineoplastic busulfan were administered to rats and compared with the commercial Busilvex®. Abstract : Nanoparticles of a mesoporous iron(iii ) trimesate MIL-100 nanocarrier encapsulating high amounts of the challenging antineoplastic busulfan were administered to rats and compared with the commercial Busilvex®. Large differences in serum concentration of both busulfan and trimesate revealed the great impact of drug encapsulation both on the drug and on nanoparticle pharmacokinetics during the first 24 h of administration.